Bionano Genomics, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
BNGO$1.16+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $9,173,000 | $17,948,000 |
| Investments | 302,000 | 48,823,000 |
| Accounts receivable, net | 4,752,000 | 9,319,000 |
| Inventory | 11,121,000 | 22,892,000 |
| Prepaid expenses and other current assets | 3,141,000 | 6,019,000 |
| Restricted investments | 11,000,000 | 35,117,000 |
| Total current assets | 39,489,000 | 140,118,000 |
| Restricted cash | 400,000 | 400,000 |
| Property and equipment, net | 19,219,000 | 23,345,000 |
| Operating lease right-of-use assets | 1,804,000 | 5,633,000 |
| Finance lease right-of-use assets | 3,299,000 | 3,503,000 |
| Intangible assets, net | 9,705,000 | 33,974,000 |
| Other long-term assets | 2,754,000 | 7,431,000 |
| Total assets | $76,670,000 | $214,404,000 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $6,962,000 | $10,384,000 |
| Accrued expenses | 5,641,000 | 8,089,000 |
| Contract liabilities | 1,128,000 | 783,000 |
| Operating lease liability | 2,991,000 | 2,163,000 |
| Finance lease liability | 260,000 | 272,000 |
| Purchase option liability (at fair value) | — | 8,534,000 |
| Convertible debentures and High Trail notes payable (at fair value) | 20,362,000 | 69,803,000 |
| Total current liabilities | 37,344,000 | 100,028,000 |
| Operating lease liability, net of current portion | 145,000 | 3,590,000 |
| Finance lease liability, net of current portion | 3,539,000 | 3,585,000 |
| Contingent consideration | — | 10,890,000 |
| Long-term contract liabilities | 267,000 | 154,000 |
| Total liabilities | $41,295,000 | $118,247,000 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value, 400,000,000 shares authorized at December 31, 2024 and 2023; 1,865,400 and 762,533 shares issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Additional paid-in capital | 728,573,000 | 677,342,000 |
| Accumulated deficit | (693,225,000) | (581,208,000) |
| Accumulated other comprehensive income | 27,000 | 23,000 |
| Total stockholders’ equity | 35,375,000 | 96,157,000 |
| Total liabilities and stockholders’ equity | $76,670,000 | $214,404,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.